12/20/2025
"Not a cure...but a meaningful step forward"
Hydralazine & Glioblastoma: A Step Forward in Research
A recent peer-reviewed study published in Science Advances by researchers at the University of Pennsylvania found that hydralazine, a long-standing blood pressure medication, was able to halt glioblastoma cell growth in laboratory studies by forcing the cells into senescence, a non-dividing state.
This research is PRECLINCAL and hydralazine is not a cure for glioblastoma. The duration and real-world effectiveness of this response in patients remain unknown. Clinical trials would be required before this approach could be used in treatment.
For an aggressive cancer with limited options, research that identifies new ways to slow tumor growth represents meaningful progress and progress matters.
Not a cure...but a meaningful step forward.
Hydralazine shows promise in laboratory studies by halting glioblastoma cell growth through senescence. Science moves forward one step at a time.